Brazil Companion Animal Cardiac Drugs Market Size & Outlook
The companion animal cardiac drugs market in Brazil is expected to reach a projected revenue of US$ 130.5 million by 2033. A compound annual growth rate of 7.84% is expected of Brazil companion animal cardiac drugs market from 2026 to 2033.
Brazil companion animal cardiac drugs market highlights
The Brazil companion animal cardiac drugs market generated a revenue of USD 72.4 million in 2025 and is expected to reach USD 130.5 million by 2033.
The Brazil market is expected to grow at a CAGR of 7.84% from 2026 to 2033.
In terms of segment, dogs was the largest revenue generating animal type in 2025.
Cats is the most lucrative animal type segment registering the fastest growth during the forecast period.
Companion animal cardiac drugs market data book summary
Market revenue in 2025
USD 72.4 million
Market revenue in 2033
USD 130.5 million
Growth rate
7.84% (CAGR from 2026 to 2033)
Largest segment
Dogs
Fastest growing segment
Cats
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Dogs, Cats, Horses, Others Animal Type
Key market players worldwide
Boehringer Ingelheim, CEVA Inc, Elanco Animal Health Inc, Virbac SA, Zoetis Inc Class A, Dechra Pharmaceuticals, Bimeda, Biogenesis Bago, Merck KGaA, Vetoquinol SA
Other key industry trends
In terms of revenue, Brazil accounted for 3.6% of the global companion animal cardiac drugs market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Latin America, Brazil companion animal cardiac drugs market is projected to lead the regional market in terms of revenue in 2033.
Argentina is the fastest growing regional market in Latin America and is projected to reach USD 43.5 million by 2033.
Brazil Companion Animal Cardiac Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Companion Animal Cardiac Drugs Market Outlook will help companies and investors design strategic landscapes.
Dogs was the largest segment with a revenue share of 70.17% in 2025.
Horizon Databook has segmented the Brazil companion animal cardiac drugs market based on dogs, cats, horses, others animal type covering the revenue growth of each sub-segment from 2021 to 2033.
Brazil Companion Animal Cardiac Drugs Market Animal Type Outlook (Revenue, USD Million , 2021-2033)
Dogs
Cats
Horses
Others Animal Type
Brazil Companion Animal Cardiac Drugs Market Product Outlook (Revenue, USD Million , 2021-2033)
Pimobendan
Spironolactone and Benazepril Hydrochloride
Furosemide
Others Product
Brazil Companion Animal Cardiac Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
Congestive Heart Failure
Myocardial (Heart Muscle) Disease
Arrhythmias
Others Indication
Brazil Companion Animal Cardiac Drugs Market End Use Outlook (Revenue, USD Million , 2021-2033)
Veterinary Hospitals & Clinics
Others End Use
Brazil Companion Animal Cardiac Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital/ Clinic Pharmacy
Retail
E-Commerce
Reasons to subscribe to Companion Animal Cardiac Drugs Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Companion Animal Cardiac Drugs Market Outlook databook
Our clientele includes a mix of Companion Animal Cardiac Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil Companion Animal Cardiac Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Brazil Companion Animal Cardiac Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Brazil Companion Animal Cardiac Drugs Market, 2021-2033 (US$M)